Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after cacillus Calmette-Guerin
Urologic Oncology: Seminars and Original Investigations, 05/22/2012
Clinical Article
Dinney CPN et al. – Two trials of valrubicin in patients with carcinoma in situ demonstrate a consistent degree of efficacy in highly pretreated patients and those with fewer previous therapies.



